Abbie Siebenhaar, PA
Medical · Salt Lake City, UTNPI 1295003234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 476 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 24.8% of the total. Among medical clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$830
- Takeda Pharmaceuticals U.S.A., Inc.$548
- Sanofi$272
- Gilead$216
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,62098%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,671 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 126 | $1,200 |
| Johnson & Johnson | 54 | $830 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $548 |
| Sanofi | 16 | $272 |
| Gilead | 11 | $216 |
| Organon | 18 | $213 |
| QOL Medical, LLC | 13 | $186 |
| Regeneron Healthcare Solutions, Inc. | 7 | $131 |
| Pfizer | 7 | $129 |
| Ferring Pharmaceuticals Inc. | 9 | $125 |
| Ardelyx, Inc. | 7 | $123 |
| Celltrion USA Inc. | 6 | $122 |
| Bristol Myers Squibb | 7 | $122 |
| AMAG Pharmaceuticals, Inc. | 3 | $97 |
| Lilly USA, LLC | 5 | $89 |
| Ipsen Biopharmaceuticals, Inc | 4 | $78 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Intercept Pharmaceuticals, Inc. | 4 | $59 |
| Orphalan Inc | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 5 | $55 |
| Madrigal Pharmaceuticals | 3 | $48 |
| Redhill Biopharma Inc. | 3 | $44 |
| Fresenius Kabi USA, LLC | 2 | $42 |
| Braintree Laboratories, Inc. | 2 | $32 |
| Novo Nordisk | 2 | $30 |
| Boehringer Ingelheim | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Digestive Care, Inc. | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$123
How this compares
$6,748 in reported general payments places this provider in the 90th percentile of 263 medical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 18 | $484,846 |
| Humira(Cf) PenAdalimumab | 33 | $265,798 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 18 | $198,741 |
| Mesalamine | 56 | $41,385 |
| LinzessLinaclotide | 37 | $34,646 |
| Dexlansoprazole DrDexlansoprazole | 32 | $10,946 |
| Rabeprazole Sodium | 105 | $6,418 |
| Omeprazole | 275 | $6,004 |
| Balsalazide Disodium | 12 | $5,688 |
| Lubiprostone | 35 | $5,118 |
| Pantoprazole Sodium | 251 | $4,845 |
| Ursodiol | 21 | $4,584 |
| Colestipol Hcl | 45 | $4,166 |
| Esomeprazole Magnesium | 40 | $2,460 |
| Famotidine | 97 | $2,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $830 | $484,84618 claims |
| AbbVieLinzess | $1,671 | $34,64637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 263 medical providers in Utah.
Other medical in Salt Lake City
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$42K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Gerald KeltySalt Lake City$6K
- Alanna JorgensenSalt Lake City$6K
- Alyssa SmithSalt Lake City$5K
- Michael SwinyerSalt Lake City$5K
- Louise TobeySalt Lake City$5K
- Jessica LathamSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.